Equities
  • Price (EUR)96.25
  • Today's Change0.23 / 0.24%
  • Shares traded0.00
  • 1 Year change5.02%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2019.
More ▼

Profile data is unavailable for this security.

About the company

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs). Its Diagnostic Solutions group includes its risk assessment services business, which offers solutions for insurers, and its healthcare information technology businesses, which offers solutions for healthcare providers. The Company's services are provided under the Quest Diagnostics brand, but it also provides services under other brands, including AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum and Care360.

  • Revenue in USD (TTM)7.57bn
  • Net income in USD708.00m
  • Incorporated1996
  • Employees46.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DGX:NYQ since
announced
Transaction
value
Boyce & Bynum Pathology Laboratories-Clinical laboratory services businessDeal completed27 Nov 201827 Nov 2018Deal completed13.28%--
Marin General Hospital-Outreach Laboratory Service OperationsAnnounced25 Oct 201825 Oct 2018Announced17.45%--
PhenoPath Laboratories PLLCDeal completed27 Sep 201827 Sep 2018Deal completed-0.06%--
Oxford Immunotec Global PLC-Laboratory Services BusinessDeal completed25 Sep 201825 Sep 2018Deal completed-0.16%170.00m
Reprosource IncDeal completed24 Sep 201824 Sep 2018Deal completed-0.18%--
Data delayed at least 15 minutes, as of Sep 20 2019 21:10 BST.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.